PMID- 31371071
OWN - NLM
STAT- MEDLINE
DCOM- 20200220
LR  - 20200220
IS  - 1532-2777 (Electronic)
IS  - 0306-9877 (Linking)
VI  - 129
DP  - 2019 Aug
TI  - A novel approach in the management of hyperhomocysteinemia.
PG  - 109245
LID - S0306-9877(19)30367-6 [pii]
LID - 10.1016/j.mehy.2019.109245 [doi]
AB  - Hyperhomocysteinemia (Hhcy) is a biochemical alteration with plasma levels of 
      homocysteine higher than 15 micromol/L, associated with atherosclerosis, and with 
      vascular thrombosis by disrupting endothelial cells. Homocysteine is a 
      sulfur-containing amino acid derived from methionine which is an essential amino 
      acid. Excess homocysteine produced in the body is expelled out by liver and 
      kidney from the systemic circulation. Hhcy is caused by the excess deficiencies 
      of the vitamins like pyridoxine (B6), folic acid (B9), or cyanocobalamin (B12). 
      High protein consumers are usually at risk for hyperhomocysteinemia because of 
      low plasma B12 levels. It is approximated that mild Hhcy occurs in 5-7% of the 
      general population and 40% in patients with vascular disease. Patients with heart 
      failure, impaired renal function, and diabetes should be screened since the 
      prevalence of Hhcy in these patients appears to be quite high. In this article, 
      we hypothesise that citicoline is a novel drug for the management of Hhcy. 
      Furthermore, the side effects of citicoline are also minimal and self-limiting. 
      If this strategy is validated, citicoline will be the cost-effective way to be 
      administered for Hhcy. Many evidences are available which suggest that ignoring 
      homocysteine levels in patients with the vascular disease would be unwise. Thus, 
      there is an urgent need for health care providers to develop effective 
      preventions and interventions program (folic acid, Vitamin B6 and Vitamin B12 
      supplementation as well as lifestyle change) to reduce this disorder.
CI  - Copyright (c) 2019 Elsevier Ltd. All rights reserved.
FAU - Qureshi, Shaiba Sana
AU  - Qureshi SS
AD  - Department of Pharmacology, Institute of Pharmaceutical Research, GLA University, 
      Mathura 281406, UP, India.
FAU - Gupta, Jeetendra Kumar
AU  - Gupta JK
AD  - Department of Pharmacology, Institute of Pharmaceutical Research, GLA University, 
      Mathura 281406, UP, India. Electronic address: jkgupta81@rediffmail.com.
FAU - Goyal, Ahsas
AU  - Goyal A
AD  - Department of Pharmacology, Institute of Pharmaceutical Research, GLA University, 
      Mathura 281406, UP, India.
FAU - Narayan Yadav, Harlokesh
AU  - Narayan Yadav H
AD  - All India Institute of Medical Sciences (AIIMS), New Delhi 110029, India.
LA  - eng
PT  - Journal Article
DEP - 20190523
PL  - United States
TA  - Med Hypotheses
JT  - Medical hypotheses
JID - 7505668
RN  - 0LVT1QZ0BA (Homocysteine)
RN  - 536BQ2JVC7 (Cytidine Diphosphate Choline)
RN  - 8059-24-3 (Vitamin B 6)
RN  - 935E97BOY8 (Folic Acid)
RN  - AE28F7PNPL (Methionine)
RN  - EC 1.1.- (Alcohol Oxidoreductases)
RN  - EC 1.1.3.17 (choline oxidase)
RN  - N91BDP6H0X (Choline)
RN  - P6YC3EG204 (Vitamin B 12)
SB  - IM
MH  - Alcohol Oxidoreductases/metabolism
MH  - Animals
MH  - Choline/therapeutic use
MH  - Cytidine Diphosphate Choline/therapeutic use
MH  - Dietary Supplements
MH  - Endothelial Cells
MH  - Folic Acid/*therapeutic use
MH  - Homocysteine/metabolism
MH  - Humans
MH  - Hydrolysis
MH  - Hyperhomocysteinemia/complications/*therapy
MH  - Kidney/metabolism/physiopathology
MH  - Life Style
MH  - Liver/metabolism
MH  - Methionine/metabolism
MH  - Models, Theoretical
MH  - Vitamin B 12/*therapeutic use
MH  - Vitamin B 6/*therapeutic use
OTO - NOTNLM
OT  - Atherosclerosis
OT  - Citicoline
OT  - Hyperhomocysteinemia
OT  - Stroke
OT  - Vitamin B12
OT  - Vitamin B6
EDAT- 2019/08/03 06:00
MHDA- 2020/02/23 06:00
CRDT- 2019/08/03 06:00
PHST- 2019/04/03 00:00 [received]
PHST- 2019/05/22 00:00 [accepted]
PHST- 2019/08/03 06:00 [entrez]
PHST- 2019/08/03 06:00 [pubmed]
PHST- 2020/02/23 06:00 [medline]
AID - S0306-9877(19)30367-6 [pii]
AID - 10.1016/j.mehy.2019.109245 [doi]
PST - ppublish
SO  - Med Hypotheses. 2019 Aug;129:109245. doi: 10.1016/j.mehy.2019.109245. Epub 2019 
      May 23.